A Phase Ib Study of the Safety and Pharmacology of Atezolizumab Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma or Atezolizumab Administered With Obinutuzumab or Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Jul 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Obinutuzumab; Tazemetostat
Indications Diffuse large B cell lymphoma; Follicular lymphoma
Focus Adverse reactions
Sponsors Roche

Most Recent Events

02 Jul 2019 Planned End Date changed from 1 May 2019 to 1 Oct 2019.
02 Jul 2019 Planned primary completion date changed from 1 May 2019 to 1 Oct 2019.
31 Aug 2018 Biomarkers information updated

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight